Search | Syneos Health Communications

#1

Keri McDonough, our communications and advocacy relations strategist, lays out our top 10 recommendations for meaningful patient advocacy group engagement on the runway to launch and beyond.

#2

As anticipated, on June 6, 2018, Senator Claire McCaskill (D-Mo.) introduced the Patient Advocacy Transparency Act.

#3

Patient advocacy has evolved over time, and with it, patient advocate archetypes have emerged.

#4

Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.

#5

Keri McDonough, one of our patient advocacy specialists, provides ten recommendations on how to meaningfully engage with patient advocacy groups throughout the lifecycle of a product.

#6

And, turns out, it’s what patient advocacy groups want from pharma, too.

#7

In 2018, pharma-advocacy partnerships made headlines for their incredible work but also caught heat over payments.

#8

Representatives from small and big pharma, and those fighting both rare diseases and more prevalent ones, came together in San Diego recently for WIB-Southern California: The Growing Importance of Patient Advocacy in BioPharma.

#9

As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis.

#10

Live From Lions Health: Nearly 2/3s of the world’s developed countries have a ban on gay and bisexual men donating blood.

#11

At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.

#12

Collaboration between advocacy groups and the healthcare industry can lead to better treatments, more engaged relationships and better quality of care.

#13

Jeanine O'Kane and Marie Emms, senior executives at Syneos Health, address rare disease pricing and the ties between manufacturers, payers and patient advocacy groups.

#14

In this guest blog, Keri Mcdonough, Lead, Advocacy and Patient Relations at Syneos Health Communications shares her insight on how to assemble a patient advisory board that accurately and effectively represents the patient voice.

#15

Keri McDonough, Patient Advocacy Lead at Syneos Health Communications, was featured in MedCity News discussing how CROs can highlight the practical and socioeconomic barriers to greater trial diversity.

#16

Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".

#17

Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.

#18

Learn about why it's still important to consider a human approach in healthcare communications from Jeanine O'Kane, President, Public Relations Group at inVentiv Health Communications.

#19

Syneos Health Communications – the portfolio of Syneos Health® agencies designed to deliver insights-driven integrated communications spanning advertising, public relations, patient advocacy, medical communications

#20

Alex Ferrara, Director, Corporate Communications, INC Research/inVentiv Health is presenting on the topic "How To Activate Employees As Advocates On Social And Digital Channels" at the Strategic Internal Communications for Health Care conference on September 13th.

#21

Live from EFP ‘18: This afternoon, a panel of 5 patients, advocates and pharma-patient connectors engaged in a discussion titled, “Where is the trust?

#22

Shortages of critical cancer-fighting drugs have impacted 83% of U.S. oncologists in the past six months.* Around the world, doctors are negotiating availability, access and funding for the infusions they most want to prescribe.

#23

PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval.

#24

Mark Baglin, Vice President of Global Marketing at Alnylam Pharmaceuticals, works in ultra ultra rare diseases, like Hereditary ATTR Amyloidosis.

#25

I’ve been frustrated with the process of buying glasses for some time now.

#26

Global PR agency pioneering health communications programs that engage key stakeholders throughout the product lifecycle

#27

This month, Janssen launched Cancer.com, aiming to create an online destination for all things oncology.

#28

In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.

#29

In just the past five years, significant changes have occurred in how new drugs come to market.

#30

This summer, students in California Institute for Regenerative Medicine’s Bridges to Stem Cell Research and Therapy program at California State University (CSU) San Marcos had new lab partners: families impacted by rare diseases.

Search Results

Connect

Site

Search Results

Connect

Site

Subscribe to our RSS feed